Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03277352 · OUTCOME

Phase 1 & Phase 2: Overall Survival

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies · Source last updated 2021-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
At 1 year and 2 years.

What was measured

Defined as the time from the start of combination therapy until death due to any cause.

Analysis population: The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.

Groups in this outcome

INCAGN01876 + Pembrolizumab + Epacadostat

INCAGN01876 in combination with pembrolizumab and epacadostat

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCAGN01876 + Pembrolizumab + Epacadostat10

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
INCAGN01876 + Pembrolizumab + Epacadostat25.59Not reported16.76NAupper limit is not estimable
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        upper limit is not estimable
        group Id
        OG000
        lower Limit
        16.76
        upper Limit
        NA
        value
        25.59
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Defined as the time from the start of combination therapy until death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    INCAGN01876 in combination with pembrolizumab and epacadostat
    id
    OG000
    title
    INCAGN01876 + Pembrolizumab + Epacadostat
param Type
MEDIAN
population Description
The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.
reporting Status
POSTED
time Frame
At 1 year and 2 years.
title
Phase 1 & Phase 2: Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice